Search

Search Constraints

You searched for: Author/Creator Fimiani, Fabio

Search Results

1. 760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. (8th December 2021)

2. 785 Sodium–glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk. (8th December 2021)

3. Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. Issue 2 (February 2018)

4. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition. (30th January 2020)

5. Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors polymorphisms?. (15th November 2015)

6. Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry. (13th May 2021)

7. From Femoral to Radial Approach in Coronary Intervention: Review of the Literature and 6 Years Single-Center Experience. (April 2017)

8. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. (29th August 2020)

9. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. (March 2020)

10. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. Issue 3 (27th March 2021)